Gene Therapy Bioassays Market Forecast 2026–2035 with Industry Insights

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Gene Therapy Bioassays Market During 2026–2030?

The gene therapy bioassays market has seen significant and rapid growth in its size over recent years. Looking ahead, its expansion is projected to be from $1.21 billion in 2025 to $1.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.5%. The historical period’s expansion was primarily fueled by an escalation in gene therapy research initiatives, augmented viral vector manufacturing capabilities, a surge in clinical trial engagements, the establishment of standardized bioassay protocols, and heightened regulatory examination of gene therapy products.

The gene therapy bioassays market size is projected for rapid growth in the upcoming years. This market is anticipated to expand to $2.62 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 16.7%. The expected growth during the forecast period can be attributed to the increasing commercialization of gene therapies, a rising demand for high-throughput bioassay solutions, the expansion of personalized genetic medicine, growing investments in advanced cell and gene therapy pipelines, and an increasing focus on assay automation and reproducibility. Major trends identified for the forecast period include the increasing adoption of cell-based potency assays, a rising demand for viral vector characterization tests, the growing use of automated bioassay platforms, the expansion of regulatory-compliant assay validation, and an enhanced focus on functional gene expression analysis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33119&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Gene Therapy Bioassays Market?

The expansion in the volume of gene therapy clinical trials is projected to fuel market growth for gene therapy bioassays. These trials are crucial for assessing the safety, effectiveness, and biological performance of genetic treatments in human participants. The surge in these trials stems from heightened research and development activities and increased capital investment by biopharmaceutical firms aiming to fulfill unmet medical requirements with novel genetic therapies. Gene therapy bioassays are instrumental in clinical development, offering essential analytical tests to evaluate biological activity, potency, safety, and their operational mechanisms at every phase of development, with regulatory demands becoming more stringent as programs progress through clinical stages. As an illustration, the Bioindustry Association (BIA), a national trade association based in the UK, reported that in January 2026, the UK had 193 active advanced therapy clinical trials, with more than 80% specifically dedicated to gene therapies. Consequently, the rising number of gene therapy clinical trials is a significant factor propelling the gene therapy bioassays market forward.

How Are The Various Segments Of The Gene Therapy Bioassays Market Categorized?

The gene therapy bioassays market covered in this report is segmented –

1) By Product Type: Cell-Based Assays; Viral Vector-Based Assays; Non-Viral Vector-Based Assays; Other Product Types

2) By Service Type: Assay Development Services; Assay Validation Services; Quality Control Testing Services; Regulatory Support Services; Data Analysis And Reporting Services; Custom Bioassay Design Services

3) By Application: Research And Development; Clinical Testing; Quality Control; Other Applications

4) By End User: Biotechnology Companies; Pharmaceutical Companies; Contract Research Organizations; Academic And Research Institutes; Regulatory Laboratories

Subsegments:

1) By Cell-Based Assays: Reporter Gene Expression Assays; Cell Viability And Cytotoxicity Assays; Transduction Efficiency Assays; Functional Potency Cell Assays; Cellular Uptake And Localization Assays

2) By Viral Vector-Based Assays: Adeno Associated Virus Vector Assays; Lentiviral Vector Characterization Assays; Retroviral Vector Titer Assays; Vector Genome Integrity Assays; Infectivity And Transduction Assays

3) By Non-Viral Vector-Based Assays: Plasmid Deoxyribonucleic Acid Delivery Assays; Lipid Nanoparticle Transfection Assays; Polymeric Carrier Efficiency Assays; Physical Gene Delivery Evaluation Assays; Non Viral Vector Stability Assays

4) By Other Product Types: Immunogenicity Assessment Assays; Biodistribution And Persistence Assays; Safety And Toxicity Bioassays; Analytical Method Development Assays; Custom Gene Therapy Bioassays

What Trends Are Affecting The Expansion Of The Gene Therapy Bioassays Market?

Within the gene therapy bioassays market, major companies are increasingly concentrating on integrating artificial intelligence and machine learning into bioassay analysis. This includes applications such as AI-enabled digital PCR data interpretation, with the goal of improving accuracy, decreasing experimental variability, speeding up result delivery, and refining the evaluation of therapeutic efficacy and safety during gene therapy development. AI-enabled dPCR data interpretation employs sophisticated algorithms to automate result analysis, distinguish true signals from background noise, and precisely quantify viral genomes or vector copy number with minimal human intervention. For instance, in April 2025, QIAGEN N.V., a Germany-based molecular diagnostics company, unveiled expanded QIAcuity lentivirus solutions, which include the QIAcuity RCL Quant Kit and CGT dPCR assays. These solutions offer algorithm-driven absolute quantification, compatibility for multiplex and singleplex assays for vector genome and vector copy number analysis, and software-assisted data analysis workflows designed to support regulatory-compliant decision-making in gene therapy bioassay applications.

Who Are The Primary Competitors In The Gene Therapy Bioassays Market?

Major companies operating in the gene therapy bioassays market are Boehringer Ingelheim BioXcellence, AGC Biologics, ICON plc, Lonza Group AG, SGS SA, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc., Catalent Inc, Recipharm AB, KBI Biopharma, Syngene International Limited, QPS Holdings LLC, BioAgilytix Labs (operationally independent CRO), Oxford Biomedica plc, Viralgen Vector S.L., ProtaGene Inc., Center for Breakthrough Medicines, RoslinCT, Immunologix Labs, Genezen Laboratories

Read the full gene therapy bioassays market report here:

https://www.thebusinessresearchcompany.com/report/gene-therapy-bioassays-market-report

Which Region Currently Holds The Largest Share Of The Gene Therapy Bioassays Market?

North America was the largest region in the gene therapy bioassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy bioassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gene Therapy Bioassays Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33119&type=smp

Browse Through More Reports Similar to the Global Gene Therapy Bioassays Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795